Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Aurisco Pharmaceutical Co.,Ltd.
  6. News
  7. Summary
    605116   CNE1000042S4

AURISCO PHARMACEUTICAL CO.,LTD.

(605116)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2021.

09/21/2021 EST

Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2021. These A Shares will be under lockup for 376 days starting from 10-SEP-2020 to 21-SEP-2021. Details: The company shareholders, namely, Ningbo Zhongjin Guolian Xinde Equity Investment Partnership (Limited Partnership), Wuxi Hongshi Huiquan Equity Investment Management Center (Limited Partnership), Qiu Weihong, issuer directors, Chu Yizhou and Liu Meihua, issuer's director and general manager Chu Dingjun have agreed not to dispose of their interest for a period of 12 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect. The company controlling shareholders, namely, Zhejiang Tongben Investment Co., Ltd., Tiantai Platinum Investment Partnership (Limited Partnership), chairman and actual controller, namely, Peng Zhien, Director Qiu Peijing, Li Jianwen, Chairman of the Board of Supervisors Jin Ping, senior manager of the issuer, Xin Mingyan, Chen Jieming, Zhang Liqin, Wang Xiuyu, Li Fangfang, employee supervisor Yang Liwei have agreed not to dispose of their interest for a period of 36 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect. The controlling shareholder, namely, Tiantai Platinum Investment Management Partnership (Limited Partnership), and deputy general manager of the issuer, Wang Guoping have agreed not to dispose of their interest for a period of 60 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect.


ę S&P Capital IQ 2021
All news about AURISCO PHARMACEUTICAL CO.,LTD.
2021Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended Sept..
CI
2021Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement ..
CI
2021AURISCO PHARMACEUTICAL CO.,LTD.(SHSE : 605116) added to Shanghai Stock Exchange A Share In..
CI
2021AURISCO PHARMACEUTICAL CO.,LTD.(SHSE : 605116) added to Shanghai Stock Exchange Composite ..
CI
2021Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 3..
CI
2021Aurisco Pharmaceutical Co.,Ltd. Announces Earnings Results for the First Quarter Ended ..
CI
2021Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended Decemb..
CI
2020Yangzhou Aurisco Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 ..
CI
2020Aurisco Pharmaceutical Co.,Ltd. Announces Major Financial Indicators in 1St Three Quart..
CI
2020Aurisco Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 343.17 millio..
CI
More news
Financials
Sales 2021 819 M 129 M 129 M
Net income 2021 185 M 29,1 M 29,1 M
Net Debt 2021 - - -
P/E ratio 2021 56,4x
Yield 2021 -
Capitalization 10 406 M 1 639 M 1 639 M
Capi. / Sales 2021 12,7x
Capi. / Sales 2022 11,5x
Nbr of Employees 939
Free-Float -
Chart AURISCO PHARMACEUTICAL CO.,LTD.
Duration : Period :
Aurisco Pharmaceutical Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 25,95 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Ding Jun Chu Chief Executive Officer & Director
Xiu Yu Wang Chief Financial Officer
Zhi An Peng Chairman
Ping Jin Chairman-Supervisory Board
De Fa Zhang Chief Engineer & Production Manager
Sector and Competitors
1st jan.Capi. (M$)
AURISCO PHARMACEUTICAL CO.,LTD.17.85%1 489
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317